Galecto (GLTO)
(Delayed Data from NSDQ)
$0.55 USD
+0.03 (5.80%)
Updated Jul 12, 2024 03:58 PM ET
After-Market: $0.54 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLTO 0.55 +0.03(5.80%)
Will GLTO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GLTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLTO
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
New Strong Buy Stocks for February 14th
GLTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Other News for GLTO
Analysts’ Top Healthcare Picks: Sagimet Biosciences, Inc. Class A (SGMT), Galecto (GLTO)
Galecto price target lowered by $1 at Oppenheimer, here's why
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto enrolls first patient in GB1211 trial